The 50-year tenure of Physics in Medicine and Biology
Introduction
The distinguished 50-year tenure of Physics in Medicine and Biology has coincided with some of the most important radiological physics innovations, including the development of nuclear reactors, new particle accelerators, three-dimensional (3D) imaging and computerassisted planning. These developments, along with conceptual advances in radiation transport, have had a dramatic impact on the practice of brachytherapy. By combining technological opportunity with clinical need, brachytherapy has continued to serve as an important and rapidly evolving tool in the radiotherapeutic armamentarium for cancer management. In the author's opinion, the most notable milestones during the last 50-60 years of brachytherapy are (1) new radioisotopes and afterloading technologies that significantly expanded clinical applications of brachytherapy (1950s-1970s) ; (2) the introduction of individualized anatomy-based dose evaluation; (3) quantitative dosimetry.
Each of these developments will be reviewed in the sections below.
Historical developments from 1950 to 1970 (which predate the author's association with radiation oncology) were researched by searching the National Library of Medicine's extended 'Old MEDLINE' database for articles from selected journals (Radiology, American Journal of Roentgenology, British Journal of Radiology, Acta Radiologica and Physics in Medicine and Biology) having titles containing selected keywords (caesium, iridium, cobalt, interstitial, intracavitary, implant, radium, afterloading, iodine, cervix, brachytherapy) . In addition, a number of contemporaneous textbooks, memoirs and other articles cited below were reviewed. This review largely, but not exclusively, emphasizes the development of brachytherapy in North America.
Brachytherapy in 1950
By the early 1950s, brachytherapy had become a well-established and mature modality. As is true today, intracavitary brachytherapy was used to deliver most of the central tumour dose for cervical cancer patients. Radium-226 tubes with 1 mm Pt filtration remained the dominant intracavitary source through the late 1960s (Krabbenhoft 1958) . In the US, a wide variety of applicator systems were in use, including preloaded Manchester ovoids at Washington University (Perez et al 1991, Tod and Meredith 1953) , Paris system-like 'Kaplan' applicators at the University of Minnesota (Stenstrom 1957) and Stockholm system 'Morris' applicators at Yale University (Nath et al 1991) . The Fletcher applicator, the most widely used vaginal colpostat in the US today, was introduced in 1953 (Fletcher 1953) . Interstitial brachytherapy was also widely used. The Holt Radium Institute reported performing 500 interstitial procedures per year in the early 1950s, of which half were single-plane permanent 222 Rn seed implants with the most frequent indication being skin cancer (Farr 1953 , Meredith 1951 . In the UK, well-standardized 226 Ra needles (Meredith 1967) were used for implanting other sites. In the US, most interstitial implants were permanent 222 Rn seed implants until low linear activity 226 Ra needles became widely available in the 1940s (Martin 1949 , Quimby 1956 ).
However, the role of brachytherapy in the 1950s was not secure. Perhaps, the most revolutionary of all radiotherapy developments, megavoltage beam therapy, was well underway, permitting delivery of doses to deep tumours competitive with those achievable by brachytherapy. Efforts to improve the penetration of external beam therapy included teleradium, supervoltage (500-800 kVp) x-ray beams (Rose and Loughridge 1936) , the 2 MV Van de Graff generator (Trump et al 1947) and the high-energy betatron (Adams et al 1949) . Broad market penetration of megavoltage radiation therapy was made possible by 60 Co teletherapy, first introduced at the University of Saskatchewan (Johns et al 1951 and MD Anderson Hospital (Grimmett et al 1952 . By 1956 , there were more than 80 such units in operation in North America alone (Brucer 1956b) .
The literature of the late 1950s makes clear that radiation oncologists were well aware of the disadvantages of brachytherapy. Classical radium needles were rigid structures with outer diameters of 1.65 mm or more. High levels of surgical skill were needed to position such needles with sufficient accuracy and regularity to achieve good clinical outcomes. Brachytherapists had to work quickly to avoid excessive personnel doses to themselves and their support staff (Quimby 1956 , Simon 1965 . Given these disadvantages, many medical centres opted for surgical or supervoltage beam therapy alternatives, which limited the number of adequate training opportunities for rigid needle interstitial implantation (Krabbenhoft 1958 , Simon et al 1972 . While data quantifying mid-20th century clinical practices are lacking, one receives the impression that, except for gynaecological brachytherapy, interstitial brachytherapy was in decline during the 1950s and 1960s. Marshall Brucer, MD (1913 -1994 , about 1960. American pioneer in the introduction of artificial radionuclides in brachytherapy. Chairman (1948 Chairman ( -1962 of Medical Division of the Oak Ridge Institute for Nuclear Studies and founding president of the Society of Nuclear Medicine. (From Ketchum (1987) with permission.)
Artificial radionuclides for brachytherapy
Artificial radioactivity induced by particle accelerators was first reported by Curie and JoliotCurie (1934) . However, quantities and forms of radioactivity useful for brachytherapy were not available until 1940s (Manhattan Project 1946) , when civilian applications of nuclear reactors were encouraged. In the US, reactor-produced teletherapy and brachytherapy source development was coordinated by the Medical Division of the Oak Ridge Institute for Nuclear studies, which was created by the US Atomic Energy Commission. Marshall Brucer 1 (see figure 1), an early nuclear medicine specialist, was appointed its first chair in 1948. Along with developing one of the first cobalt teletherapy devices (Grimmett et al 1952) , his group collaborated in the design, production or dissemination of virtually all of the radium-substitute sources investigated in the US during the 1950-1965 period. In Canada and UK, the Chalk River and Harwell (Sinclair 1952) reactor sites made important contributions to medical use of artificial radionuclides.
Temporary brachytherapy radionuclides and afterloading techniques
Cobalt-60 ( 60 Co) was one of the first artificial radionuclides applied to brachytherapy in the form of interstitial needles and wires (Brucer 1952 , Morton et al 1951 , Myers 1948 and intracavitary tubes (Wilson 1951) . Beyond improving upon the cost effectiveness and radiochemical safety of radium therapy, 60 Co seemed to do little to advance the clinical art of brachytherapy. In addition, its relatively short half-life (5.26 years) increased the complexity of low dose-rate (LDR) implant techniques, many of which emphasized the importance of fixed low dose rates (Paterson 1948 longer tenure in radiation oncology, first as a teletherapy source in the early 1950s (Brucer 1956c) and as a substitute for 226 Ra in LDR needles and intracavitary sources beginning in the 1960s. Both Amersham in the UK (Horsler et al 1964) and 3M in the US (Horwitz et al 1964) introduced intracavitary products by 1960, the former using caesium bound to a silver metallic matrix and the latter incorporating radioactive caesium chloride sintered within zirconium phosphate microspheres (Ryan 1964) . Sealing the relatively toxic caesium salts in a sintered ceramic or glass core was an important technical advance and was eventually incorporated into all modern commercial 137 Cs sources. From the late 1970s to the present day, 137 Cs tubes were used almost exclusively for LDR intracavitary brachytherapy due to their lower costs of disposal and radiation safety hazards. As of 2002, the last 137 Cs source manufacturer ceased operations, effectively ensuring that HDR intracavitary techniques will come to dominate gynaecological brachytherapy.
Two artificial radionuclides that had far-reaching impact on expanding brachytherapy clinical applications were 182 Ta (Sinclair 1952 ) (110-day half-life, 1.1 MeV mean photon energy) and 192 Ir (74.2-day half-life, 0.40 MeV mean photon energy). 182 Ta wires were inserted interstitially using hypodermic needles, thus serving as more flexible and versatile replacements for radium needles in temporary interstitial implants (Ellis 1956) .
192 Ir appears to have been introduced by Henschke (1957 Henschke ( , 1958 in 1956 for permanent implantation of lung and prostate tumours: earlier reviews (Brucer 1952 , Mitchell 1946 do not mention 192 Ir, despite the fact it has a much higher neutron activation cross section and specific activity than 182 Ta. By the early 1960s (Chase et al 1961 , Henschke et al 1963 , Simon 1965 Ir seeds, encapsulated in nylon ribbons, had been introduced as temporary implant sources in conjunction with a fully afterloadable applicator system (figure 2). In Europe, afterloading implantation of iridium wire was introduced in the context of the Paris system of brachytherapy (Chassagne et al 1963) . Surgically implanted flexible hollow tubes, into which either (Walstam 1962 ). An LDR source train at the end of a flexible capable was used to move the source to and from the patient to a shielded safe under control of an automatic timer. A radiation detector was used to verify source position.
non-radioactive dummy ribbons (for imaging) or radioactive ribbons (for treatment) could be afterloaded, were used, completely eliminating operating room staff exposure. The result was a low-cost, reduced-diameter flexible radioactive source that made even single-uses costeffective in many clinics. Compared to 226 Ra needles, the flexible afterloading applicators and the source active length could be much more easily and comfortably adapted to the patient's anatomy, effectively increasing domain of implantable tumours and number of qualified operators. These innovations contributed to a renaissance of interstitial brachytherapy, as evidenced by the growth of the Paris system of definitive brachytherapy for early-stage tumours and US approaches for treating large pelvic masses Feder 1977, Syed et al 2001) .
A related innovation in brachytherapy was remote afterloading technology, in which sources are robotically transported from a shielded safe to their treatment position in the implanted applicators. Initially, this technology (figure 3) was introduced by Walstam (1962) and Henschke et al (1964 Henschke et al ( , 1966 in the early 1960s for the purpose of reducing personnel exposures from low and medium dose-rate intracavitary brachytherapy using 137 Cs or 226 Ra sources. Soon thereafter, high dose-rate (HDR) brachytherapy was introduced (O'Connell et al 1965) , in which fractionated treatments lasting only a few minutes are administered. In this application, 60 Co pellets, which never achieved broad acceptance in manual brachytherapy, played an important role. The spherical 60 Co pellets had sufficient specific activity that dose rates of 2 Gy min -1 could be sustained in normal diameter intracavitary applicators. By varying the dwell time, radioactive decay could be compensated for. In the 1970s, the first single-stepping source remote afterloading system was introduced (Gauwerky 1977 , Schulz et al 1984 , using a miniaturized high intensity 192 Ir source welded onto the end of a flexible drive cable. The high specific activity of 192 Ir permitted development of sources with outer diameters of 1.1 mm or less (Gauwerky 1977) , so that HDR brachytherapy could be applied to interstitial techniques. The ability to manipulate individual dwell times and positions offered the potential to improve implant dose distributions via formal optimization techniques (Anacak et al 1997 , Lessard et al 2002 . Except for permanent seed brachytherapy, the majority of temporary interstitial and intracavitary treatments in the US now appear to be delivered by HDR techniques.
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Permanent brachytherapy sources and techniques
One of the first alternatives to 222 Rn seeds to be investigated was radioactive 198 Au wires (supplied by ORNL) encapsulated in gold tubing. Radiogold seeds were introduced by Henschke and colleagues at Ohio University in 1951 (Henschke 1953, Myers and Colmery 1952) . To compensate for the rapid radioactive decay arising from the 2.7-day half-life of 198 Au and to customize source strength to the particular patient, the length of the radioactive wire was adjusted. The Ohio University group developed both permanent and temporary interstitial implant techniques, including an early form of afterloading (Morton et al 1951) . Nylon tubes were preloaded with radioactive seeds and spacers. Dummy wires or nylon tubes loaded with dummies were inserted surgically into the tumour and localization radiographs obtained. The radioactive nylon assemblies were then pulled into place after attachment to the trailing end of the dummy applicator. To this day, a few programs (Teh et al 1998) 198 Au sources never achieved wide utilization. An important development was the introduction of interstitial seeds using electron-capture decay radionuclides, with moderately long half-lives of 10-60 days that emit a cascade of lowenergy (20-40 keV) characteristic x-rays and γ -rays. The first practical K-capture source, 125 I (half-life: 59.6 days; mean energy: 28 keV) encapsulated in titanium seeds, was developed by Donald C Lawrence (Lawrence et al 1966) in the early 1960s and was investigated clinically in 1965 by Hilaris et al (1968) at Memorial Sloan-Kettering Hospital. While many tumour sites were implanted, including lung cancer (Hilaris et al 1976) , prostate 125 I seed implantation, performed intraoperatively during pelvic lymphadectomy (Hilaris et al 1974) , has had the most enduring impact. Other important radionuclides are 103 Pd (17.0-day half-life and 22 keV mean energy), introduced by John Russell in 1987, and 131 Cs (9.6-day half-life and 29 keV mean energy), which was initially proposed by Lawrence and Henschke (Henschke and Lawrence 1965) but has only recently become available commercially (Murphy et al 2004) . The lowenergy photons emitted by these sources dramatically reduce external exposure hazards: an 8 cm thickness of tissue reduces exposure ten-fold. Thin (0.2 mm) lead foils produce almost complete shielding. Thus, patients need not be confined to the hospital solely for radiation safety reasons. Clearly, the 1950s clinical experience with ultralow dose-rate 192 Ir implantation (Henschke 1958 ) was a critical factor in the success of this technique.
The introduction of transrectal ultrasound (TRUS)-guided transperineal implants (Holm et al 1983) both improved the accuracy with which permanent brachytherapy could be delivered to the prostate and eliminated the need for a highly invasive surgical procedure to expose the prostate (figure 4). The technique was further developed and investigated by the Seattle group, led by John Blasko (Blasko et al 1993) . Ten-year survival data (Grimm et al 2001 , Sylvester et al 2003 now demonstrate that brachytherapy, either as sole treatment for low-risk patients or in combination with external beam radiation for higher risk disease, results in biochemical relapse-free survival rates comparable to or superior to radical prostatectomy and definitive external beam therapy. The attraction of a one-day procedure along with a favourable profile of normal tissue complications has resulted in exponential growth of this modality. The number of procedures in the US has grown from less than 5000 in 1995 to 40 000-60 000 in 2002 (Grimm and Sylvester 2004 ) (30-40% of all eligible patients diagnosed annually in the US), challenging radical prostatectomy as the standard of treatment. In response to this growth, the number of commercially available low-energy interstitial seed products has increased to 24 from 3 in 1999 (Rivard et al 2004) . As discussed below, this trend has resulted in significant improvements in low-energy source dosimetry and image-guided brachytherapy.
Evolution of brachytherapy planning methodology
Prescription of brachytherapy in terms of exposure was commonplace in the early 1950s except for mg-h-based intracavitary brachytherapy systems. Interstitial brachytherapy applications were generally based upon the Quimby (Quimby and Castro 1953) or Manchester (Meredith 1967 ) implant systems. The distribution rules of these systems specified the geometric arrangement of radium needles relative to the target volume boundaries. Manual aids, such as tables giving exposure/mg-h as a function of implanted volume or area, were used to estimate the prescribed exposure to a well-defined dose-specification criterion for the idealized needle arrangements recognized by the system. The literature of the time, e.g. De Forest Smith (1958) and Farr (1953) , describes many ingenious techniques for deriving effective implanted area or volume from planar radiographs. From the estimated reference dose rate, the treatment time needed to deliver the prescribed dose was estimated. It was recognized that implants frequently deviated significantly from the idealized source arrangements allowed by the system rules (Meredith 1951) . Numerous approaches for more accurately controlling dose delivery were investigated, including small interstitially inserted ion chambers (Nuttall and Spiers 1946) and scale models of implants built from radiographic projections that could be used to support direct physical measurements. Meredith's excellent review of dose control (Meredith 1951) notes that dose measurements in rapidly varying radiation fields were difficult to interpret. Dose-rate distributions around individual needles or tubes were estimated (Greenfield et al 1959) by integrating an isotropic point-source kernels over the extended radioactivity distribution within the source, which modelled by an encapsulated line source by the Sievert integral algorithm. Such models require tissue-buildup factors (ratio of exposure in medium to exposure in free space at same distance from a point source) and effective attenuation coefficients of the encapsulating and active core media, along with the physical and active source dimensions. The point-source kernel parameters were assumed to depend only on the radionuclide photon spectrum . Shalek and Stovall (1969) have reviewed the application of this model to radium tubes and needles. Sievert models, more generally called 1D pathlength dose-calculation algorithms, were quickly extended to artificial radionuclides (Krishnaswamy 1972) including 125 I seeds (Krishnaswamy 1978) even though the validity of the model was questioned at such low energies. The evolution of dose-calculations methods has been reviewed elsewhere for 137 Cs (Williamson 1988a (Williamson , 1998 ) and lower energy sources (Williamson 1996) .
Three developments in brachytherapy planning technology during the last 50 years have dramatically altered brachytherapy clinical practice: computer isodose calculations, 3D imaging for defining target volumes and for guiding applicator insertion, and dwellweight optimization of single-stepping source remotely afterloaded implants. While modern quantitative dosimetry methods confirm that 1950-era single-source dose calculations were quite accurate in many cases, manual source-superposition calculations about arrays of arbitrarily oriented sources were simply not feasible until the introduction of computerassisted planning in the 1960s (Hope et al 1964 , Nelson and Meurk 1958 , Shalek and Stovall 1961 . By evaluating isodose curves in selected planes for the geometric arrangements of needles, wires and intracavitary tubes actually achieved clinically, the prescribed dose could be based on delivered doses rather than intended doses derived from an abstract idealization of the implant. Subsequent innovations included fully 3D dose calculations and dose-volume histogram (DVH) indices for quantifying dose delivery and implant quality (Anderson 1986, Saw and Suntharalingam 1988) .
The second development, use of x-ray computed tomography (CT) and other 3D imaging modalities in interstitial (Herskovic et al 1980, Pierquin and Fayos 1962) and intracavitary (Ling et al 1987 , Schoeppel et al 1994 brachytherapy planning, constituted a radical departure from the purely surgical practice of brachytherapy. Localization of the clinical target volume (CTV) and dose-limiting normal tissues relative to the implanted sources allowed absorbed dose to be specified using anatomy-based coverage indices that are more likely to correlate with clinical outcome than the non-anatomic dose-specification quantities used by the classical systems. Intraoperative imaging to guide applicator insertion in principle makes the position of the implanted sources free parameters for optimizing the dose distribution with respect to CTV and normal tissue coverage. Image-guided brachytherapy techniques were first developed for stereotactically guided brain implants in the late 1980s (Weaver 1995) . TRUS-guided permanent (Blasko et al 1993 , Holm et al 1983 and HDR temporary (Martinez et al 2001) implantation have become standard of practice for prostate brachytherapy in North America.
A third cluster of innovations is related to single-stepping source remote afterloading and dwell-weight optimization as a tool for improving dose uniformity and target coverage within implants. Early geometric and dose-point optimization algorithms (Edmundson 1992) were first used to create non-uniform source loadings so that the dose uniformity and target coverage nonideal patient implants could approach the quality of idealized Manchester implants. More recent approaches extended both dwell weight (Lessard et al 2002) and source position optimization (Pouliot et al 1996) based upon target and normal tissue coverage indices derived from 3D imaging.
Brachytherapy dosimetry
As used here, 'dosimetry' refers to estimation of absorbed dose by means of experimental or fundamental theoretical techniques about single brachytherapy sources. Both experimental and computational techniques have undergone substantial development during the last 50 years, driven mainly by the utilization of newer isotopes.
226 Ra dosimetry: from threshold erythema dose to semi-empirical models
Early experimental techniques for quantifying radiation fields associated with radioactive sources included the gold-leaf electroscope introduced by Becquerel in 1900 and the constant potential ionization chamber introduced by Villiard in 1908. Although absorbed doselike quantities had been defined as early as 1914 (Christen 1914) , no theory existed from which the absorbed dose or any other radiation field quantity could be inferred from the measured detector response. The first rigorously measurable field quantity, exposure, was defined in terms of specific instrument, the free-air chamber (FAC), introduced in the 1920s. FAC exposure standardization provided a sound foundation for external beam radiotherapy of the time, which was limited to x-ray spectra of 300 kVp (Wyckoff 1980) . However, the FAC could not accurately measure 226 Ra exposure rates due to the difficulty of establishing secondary charged-particle equilibrium for high-energy (about 1.2 MeV on average) radium gamma rays. In 1941, Quimby (1941) noted that experimental estimates of the 226 Ra exposurerate constant in the 1920-1940 period varied by a factor of 2. Prior to 1940, the radiological physics community struggled with problem of specifying brachytherapy treatments in a reproducible fashion. This void was filled by a number of biological and chemical dosimeters for mapping 'dose' distributions about early brachytherapy sources, including bleaching butter and tissue necrosis in rabbits (Quimby 1928 (Quimby , 1941 . By plotting the distance to effect (e.g., butter bleaching) as a function of exposure time and source strength, 'dose' fall-off as a function of distance could be inferred. Perhaps, the most widely used biological endpoint was threshold erythema dose (TED), which is defined as the dose needed to produce a barely detectable skin erythema in 80% of the subjects so irradiated. This technique, developed by Quimby and colleagues at Memorial Hospital, apparently had a reproducibility of about 10% (Dean 1923 , Quimby 1928 , 1941 and was use to intercompare radium and supervoltage beams to lower energy beams calibrated in terms of exposure.
A rigorous method for measuring exposure from radium sources was made possible in the 1930s when quantum mechanical treatments of photon scattering (Gray 1929 ) and electronenergy loss (Bethe 1930 , Bloch 1933 ) were published. This made possible the development of a practical cavity theory (Gray 1936 , Laurence 1938 , which allowed exposure to be rigorously inferred from small ion chambers with condensed matter walls thick enough to establish transient charged-particle equilibrium. By 1938, experimental estimates of ( δ ) Ra,0.5 had converged to within a few per cent of Attix's definitive 1957 measurement (Attix and Ritz 1957 ) of 8.25 R cm 2 mg −1 h −1 for radium needles filtered by 0.5 mm of Pt. To compute dose distributions about implanted 226 Ra needles and tubes, physicists employed semi-empirical computational dosimetry models . Quimby (1922) developed a numerical technique for partitioning needles into a linear array of point sources, from which away-and-along exposure tables could be inferred. This was followed by Sievert's more elegant analytical solution, the Sievert integral method, in 1923. By the late 1930s, the exposure/mg-h tables used by the Quimby (1952) and Manchester (Parker 1938 ) interstitial implant systems were based upon computed single-source dose distributions. While brachytherapy may have been in clinical decline in the early 1950s, the clinical and dosimetric techniques, upon which classical systems brachytherapy was based, were very mature. Computed exposure rates were based upon a firm foundation of national and international standards based upon standard cavity chambers.
Dosimetry during the classical era of brachytherapy
During this period, brachytherapy treatment planning made the transition from table-based systems to patient-specific 2D and 3D dose distributions. In addition, the underlying dosimetry methods successfully adapted to the replacement of radium and radon sources by artificial radionuclides. A major advance was the extension of exposure-based primary standards to the new radium-substitute sources. In the US, NIST (the National Institutes of Standards and Technology, known before 1988 as the National Bureau of Standards) developed reference exposure-rate primary standards based upon carbon wall spherical ionization chambers for 137 Cs and 60 Co sources in 1974 (Loftus 1970 ) and for 192 Ir brachytherapy sources in 1980 (Loftus 1980 ). This transition was not always free of serious mishaps. For example, 3M model 6500 137 Cs intracavitary tubes were calibrated by direct intercomparison of caesium tubes with a NIST-calibrated radium needle in a nuclear medicine re-entrant ionization chamber (Kubiatowicz 1981) from 1966 until 1979. Because this procedure ignored differences in polar anisotropy, caesium tube calibrations were overestimated by 5-9%. In contrast, the early Amersham caesium tubes avoided this error by using a carbon-wall ionization chamber to intercompare caesium sources against a calibrated radium needle (Horsler et al 1964) . In the 1980s, the quantities equivalent mass of radium and reference exposure rate were replaced by reference air-kerma rate (ICRU 1985) or, in North America, by the numerically identical quantity, air-kerma strength (S K ) (Nath et al 1987) .
The role of experimental dosimetry during the classical brachytherapy era.
Relatively few articles on experimental dosimetry were published during this era. The most influential studies focused on measurement of quantities needed to implement Sievert/1D pathlength models for various types of sources. For example, Keyser (1951) and Whyte (1955) used ion chambers to measure the attenuation of radium γ -rays by concentric cylindrical Pt filters. The resultant thickness-dependent effective filtration coefficients served as standard data for Sievert integral implementations through the 1970s Stovall 1969, Young and Batho 1964) . Due to an influential theoretical analysis (Evans and Evans 1948) , the spectrumweighted mean value of µ en was used to approximate the effective attenuation coefficient for radium-substitute radionuclides (Hall et al 1966 , Krishnaswamy 1972 .
As the clinical role of radium grew, a number of authors sought to more quantitatively map radium source dose distributions by experimental means. Commonly used instrumentation included brass-and aluminium-walled ion chambers (Nuttall and Spiers 1946, Sievert 1930) , liquid-filled ion chambers, and organic (Ter-Pogossian et al 1952) and inorganic (Hine and Friedman 1950) scintillators. It was soon recognized (Wootton et al 1954) that air ionization chambers with air-or tissue-equivalent walls were necessary to accurately quantify the small deviations of sealed-source dose distributions from inverse-square law. Such measurements reassured the community that exposure-calibrated higher energy artificial radionuclide sources indeed had dose distributions that were equivalent to 226 Ra sources of similar geometry. Another important advance was introduction of 1D Monte Carlo and deterministic solutions of the Boltzmann transport equation. The radial dose distributions arising from isotropic point sources in medium by Berger (1968) and Meisberger (Meisberger et al 1968) further refined the radionuclide-dependent tissue-attenuation and scatter-buildup factors. The standardized tables (Shalek and Stovall 1961) of recommended tissue-attenuation and scatter factors derived from these early dosimetry investigations were used to implement Sievert integral dosecomputation models that dominated brachytherapy dosimetry through the 1980s. Since 1D pathlength algorithm input parameters were assumed to depend only on the primary spectrum of the radionuclide and the encapsulating material, single-source dose distributions for sources of arbitrary design could be generated without having to perform source-specific dose measurements. Recent investigations have shown that in many cases this approximation was justified, e.g., for 192 Ir (Wang and Sloboda 1998). However, early investigators recognized the need for caution in extending this approach to very low energy 125 I brachytherapy sources (Krishnaswamy 1978) .
Beyond standardization of Sievert integral input parameters, the rather elegant scintillation ( figure 5(a) ) and thermoluminescent dosimetry (TLD) (figure 5(b)) detector methods for dose mapping were used only infrequently and had little impact on clinical practice. The classical era was clearly dominated by semi-empirical computational models. This dosimetry paradigm was perhaps most succinctly summarized by Quimby (Quimby 1956 ): "Once the output of a milligram of radium under specified conditions is known, it is not necessary to calibrate the output of every tube or needle: this can be calculated on a basis of the actual radium content, the geometrical size and shape of the source, and the filtration. Therefore the study of distribution of radiation within the tissues for a particular distribution of sources is much simpler than if large series of measurements had to be made in suitable phantoms with adequate ionization chambers. In fact, the latter would be an almost impossible procedure."
The rise of modern experimental and computational dosimetry methods
The development of modern quantitative approaches to brachytherapy dosimetry is intimately linked with clinical utilization of low-energy 125 I and 103 Pd seeds. Interest in basic experimental and computational dosimetry methods began to grow in the mid-1960s because of concerns that semi-empirical computational dose-calculation models, applied so successfully to radiumequivalent radionuclides, might not be valid for the 28 keV x-rays of 125 I. Table 1 shows the nearly two-fold historical evolution of absolute dose-rate estimates for the 3M (later Amersham and now GE Healthcare) family of sources. Dosimetry and calibration techniques used in the first decade of clinical 125 I practice are undocumented, although the original TG-43 report (appendix C in Nath et al (1995) ) hints that a very large dose-rate constant, Hilaris et al (1975) and Krishnaswamy (1978) . The 1975 Memorial study calibrated model 6702 seeds using a carbon-wall extrapolation chamber at 30 cm distance and measured transverse-axis dose rates by means of TLD rods in a Mix-D phantom. Krishnaswamy, on the other hand, derived his estimated from Berger's (1968) theoretical point-source buildup factor data. His paper included confirmatory TLD dose measurements. As shown by table 1, the two methods differed by more than 30%. In 1982, Ling (Ling et al 1983) published a somewhat updated theoretical estimate for the model 6711 seed (which was recognized to have a some different photon spectrum than the 6701 seed) along with a radial dose function table derived from silicon diode measurements. These data continued to be used by most practitioners until acceptance of the first TG-43 report in the late 1990s.
Modern experimental dosimetry and calibration methods
Development of primary air-kerma strength standard for 125 I seeds by NIST (Loftus 1984) was a major advance for low-energy seed brachytherapy. This standard was based upon the Ritz FAC (Ritz 1960) , which to this day serves as the US air-kerma standard for low-energy x-ray beams. These standardization measurements were performed in 1983 and transferred to a re-entrant ionization chamber for the 125 I seed models then available. When vendorassigned seed strengths are consistently traceable to a stable primary standard based upon accurate realization of a well-defined physical quantity, theoretical as well as experimental estimates of absolute dose rates can be made. In addition, doses delivered to groups of clinically evaluated patients treated at different times can be reconstructed consistently. One of the lessons of the quantitative dosimetry era is that calibration errors and shifts, as well as dose-measurement uncertainties, can undermine clinical dose specification and prescription uncertainty (Williamson et al , 1999 . At least for the small sample seeds used to develop the 1985 standard (denoted by S K,N85 in the recent literature), it appears that the exposure rate derived from the vendor's 'apparent activity' assay agrees closely with Loftus' measurements (Loftus 1984) .
In 1986, the US National Cancer Institute funded a 3-year multi-institutional contract to perform a definitive review of low-energy seed dosimetry. The three institutions, collectively called the Interstitial Collaborative Working Group (ICWG), consisted of Memorial SloanKettering Institute, Yale University and University of California-San Francisco led by principle investigators Lowell Anderson, Ravinder Nath and Keith Weaver, respectively . Using TLD-100 chips and powder capsules embedded in machined solid-water phantoms, the ICWG developed procedures, for calibrating TLD detectors and correcting for higher TLD response to low-energy photons, for quantitatively estimating absolute dose rates in water. Each of the three ICWG investigator groups independently measured (Chiu-Tsao et al 1990, Nath et al 1990 , Weaver et al 1989 transverse-axis dose distributions for the 125 I and 192 Ir then available to validate their TLD measurement methodology. This was followed by more complete 2D dose distributions about the extant 125 I, 192 Ir and 103 Pd brachytherapy sources (Chiu-Tsao and Anderson 1991 , Nath et al 1993 . The results showed good agreement among the different measurements and overall, but large (up to 18% as per table 1) differences between measured and classically computed dose rates for 125 I seeds, but good agreement between the classical and experimental approaches for 192 Ir. As a result of the ICWG efforts and subsequent contributions from later investigators, TLD dosimetry came to be accepted as the most reliable and best validated experimental approach in brachytherapy and its results are widely used as the basis for clinical dose computation.
The rise of modern computational dosimetry techniques
Independently of the ICWG initiative, other investigators were investigating Monte Carlo photon-transport techniques for quantitatively evaluating single-source dose distributions. Based on an accurate and detailed mathematical model of the internal structure of the source, photon histories can be generated and then evaluated to assess absorbed dose. 1D Monte Carlo simulations and other transport equation solutions have been used since the 1960s to calculate radial dose distributions arising from isotropic point sources in medium, e.g., the widely used point-source buildup factors of Berger (Berger 1968 ) and the tissue-attenuation and scatterbuildup factors of Meisberger (Meisberger et al 1968) . 1D Monte Carlo techniques were first applied to 125 I by Dale (1983) . However, Monte Carlo techniques were applied to more geometrically complex problems in brachytherapy only relatively recently. One of the earliest 3D studies (Williamson et al 1983 ) (see figure 6) used Monte Carlo simulation to assess the accuracy of the Sievert model for platinum-encapsulated 226 Ra and 192 Ir sources suspended in free space and was later extended to 137 Cs sources embedded in medium (Williamson and Seminoff 1987) . Burns and Raeside (1988) published one of the first Monte Carlo dosimetry studies based upon a geometrically realistic 125 I seed model. The author's 1988 Monte Carlo study (Williamson 1988b ) demonstrated theoretically that semi-empirical dose-calculation models indeed overestimate 125 I absolute dose rates by 10-14% and that the primary cause of this discrepancy is non-penetrating 4.5 keV titanium characteristic x-rays detected by the Ritz FAC, which artificially inflated NIST's S K,N85 estimate (figure 7). Comparisons of ICWG TLD measurements and Monte Carlo based dose distributions , Williamson 1991 showed excellent agreement. Williamson and his colleagues published a series of studies comparing Monte Carlo dose-rate predictions to silicon diode (Perera et al 1994 , Williamson et al 1993 and TLD (Das et al 1997 , 1996 , Kirov et al 1995 , Valicenti et al 1995 experimental benchmarks which established the reliability and accuracy of Monte Carlo based dose predictions across the energy spectrum of brachytherapy in both heterogeneous and homogeneous geometries. Currently, Monte Carlo simulation is a widely used and accepted dosimetry tool. For higher energy sources (mostly 192 Ir and 137 Cs sources), relatively good (<5%) agreement (at least on transverse axis) between classical dose-calculation algorithms and Figure 6 . Illustration of the geometry used to make Monte Carlo estimates of dose to a geometric point (Williamson 1987 ) from filtered line sources. (From Williamson et al (1983) with permission.) Figure 7 . Product of transverse-axis air-kerma rate and distance squared for a model 6711 seed plaque modelled by Monte Carlo techniques, showing how low-energy contaminant x-rays inflate S K,N85 by overestimating the air-attenuation correction. (From Williamson (1988b) with permission.) more contemporary computational or experimental approaches is observed (Williamson 1996 (Williamson , 1998 . For lower energy sources, single-seed dose distributions are much more sensitive to model-specific variations in source internal geometry, limiting the accuracy of semi-empirical models in this energy range .
Recent developments in low-energy seed brachytherapy
A major advance in low-energy photon brachytherapy was the 1999 implementation of a new NIST primary standard of air-kerma strength, denoted in the recent literature by S K,N99 . The new standard used the wide-angle free-air chamber (WAFAC) (Seltzer et al 2003) to realize air-kerma strength. This cylindrical FAC was designed to filter out contaminant low-energy xrays and had a larger collection volume so that that single seeds, compared to plaques of seeds for the 1985 Loftus standard, could be accurately measured. This dedicated brachytherapy WAFAC-based calibration service allows new brachytherapy sources to be added to the system of national standards as they are introduced to market and also provides the infrastructure for vendors to periodically intercompare their calibration processes with NIST so as to maintain traceability to the primary standard. On the negative side, the new S K,N99 resulted in a lowering of dose-rate constants (see table 1) relative to S K,N85 . In addition, NIST-traceable 103 Pd seed calibrations turned out to differ by more than 20% from vendor calibrations requiring a realignment of both dose-rate constants and recommended prescribed doses. In addition, the field was swamped by multiple dosimetry publications (as many as 20 different datasets for 6711 seed) and a rapidly growing array of commercially available seed models (from 3 in 1999 to over 20 in 2004) . Taken together, these developments had the potential to cause significant confusion and dose-delivery errors.
The role of the AAPM in standardizing low-energy brachytherapy dosimetry
During era of rapid growth in low-energy seed permanent implantation and shifting dosimetry standards, the AAPM has had substantial impact on the clinical practice of brachytherapy dose calculation, successfully promoting uniformity of dose-calculation practice that has benefited literally hundreds of thousands of patients. The AAPM's role in brachytherapy dose computation began with the publication of the original TG-43 report (Nath et al 1995) . Its proposed dose-calculation formalism, derived from the ICWG recommendations , used measured or Monte Carlo based single-source dose distributions rather than semi-empirical models. In addition, TG-43 reviewed the published TLD and Monte Carlo data available for the models 6711 and 6702 125 I sources, the model 200 103 Pd source and the stainless-steel-clad 192 Ir seed. For each of these sources, a consensus dataset was recommended, including dose-rate constants, anisotropy constants and factors, anisotropy functions and radial dose functions.
The 1995 TG-43 recommendations implied that 125 I dose rates were 10-15% lower than those predicted by then current dose-calculation practices. Implementation of the new S K,N99 standard (Seltzer et al 2003) necessitated another 10% change, but in the opposite direction. Because the potential for error in simultaneously modifying the source strength and absorbed dose scales by more than 10% was high, the AAPM created an Ad Hoc Working Group under the leadership of Dale Kubo to assist the community in adapting to these changes. The Working Group report (Kubo et al 1998) developed a step-by-step procedure for implementing the new WAFAC standard and the TG-43 formalism and recommended that the 125 I monotherapy prescribed dose be revised from 160 Gy to 145 Gy. In the author's opinion, the complexity of these changes motivated the community and planning software vendors to rapidly adopt the TG-43 dose-calculation formalism.
Given the rapid shift from radical prostatectomy to permanent seed implantation as the dominant modality for treatment of low-risk prostate cancer, in 1997 the AAPM created a permanent Radiation Therapy Committee (now Therapy Physics Committee Working Group (later subcommittee) on Low Energy Interstitial Brachytherapy Dosimetry or LIBD, under the leadership of Jeffrey Williamson. As LIBD's activities grew in scope, it became a permanent subcommittee (currently named 'Brachytherapy Subcommittee (BTSC)' with six Working Groups under the chairmanship of Mark Rivard). BTSC took an active role in the introduction of new source strength standards and revised dosimetry practices, coordinating efforts by NIST, source vendors, the clinical community and ADCL secondary dosimetry laboratories often on a source model-by-model basis. BTSC devised a set of dosimetry guidelines , recommending that every routinely used low-energy interstitial source product has a NIST-traceable S K vendor calibration process and independent experimental and Monte Carlo dose-rate evaluations as documented by peer-reviewed publications. These guidelines have become de facto industry standards, accepted by nearly all vendors involved in the market. BTSC also took leadership in implementing the NIST WAFAC standard for the model 200 103 Pd source in a coordinated fashion with the vendor including a historical assessment of 'administered-to-prescribed' dose ratios that enabled users to duplicate dose delivery practices of the past in the face of multiple revisions to the 103 Pd dosimetry parameters and calibration changes . In collaboration with the Radiological Physics Center, BTSC maintains an online registry 3 of brachytherapy source models and vendors that voluntarily comply with AAPM dosimetric prerequisites .
Another BTSC contribution was a major revision of the TG-43 dose-calculation formalism, the preparation of consensus dosimetry parameters for eight source models, and guidelines for the practice of TLD and Monte Carlo dosimetry (Rivard et al 2004) . A supplement to this report, including consensus dosimetry parameters for an additional 10-12 source models, is expected to be published in late 2006.
Current status of brachytherapy dosimetry and future directions
Detailed reviews of state-of-the-art brachytherapy dosimetry about 2005 are given in the updated TG-43 Report (Rivard et al 2004) and as a recent review chapter . The total combined uncertainties for TLD transverse-axis 125 I seed dosimetry are estimated to be 7.9% (1 cm) to 9.5% (5 cm). The dominant uncertainties are poor reproducibility of repeated TLD readings, uncertainties in the relative energy response correction and uncertainties in the solid-to-liquid water conversion. This last source of uncertainty can be eliminated by use of phantom materials with better-documented compositions. Using state-of-the-art photon cross sections (Cullen et al 1997) , the corresponding uncertainties of Monte Carlo based absolute dose rates are 2.5% and 5% . These uncertainties are likely to be much smaller for higher energy sources. An example of the agreement observed between measured and Monte Carlo dose-rate estimates is shown in figure 8 for 125 I seeds. Because Monte Carlo dosimetry is subject to potentially large and unpredictable systematic errors (S K standard implementation errors, presence of contaminant radionuclides, etc), both experimental and Monte Carlo dose-rate characterization continue to be indicated, at least for low-energy sources. The current BTSC practice for forming consensus datasets is to accept Monte Carlo estimates of relative dose ratios (anisotropy and radial dose functions) if they agree within experimental uncertainty with measured datasets and while forming consensus dose-rate constants by averaging candidate Monte Carlo and measured values (Rivard et al 2004) .
Ongoing research developments in brachytherapy dosimetry include the search for experimental dosimetry methods that have lower uncertainty and higher spatial resolution than TLD dosimetry. Relatively well established systems for relative dosimetry include single-element silicon diode detectors (Williamson et al 1993) and plastic scintillator probes (Bambynek et al 2000) . Polymer gel dosimetry (De Deene et al 2001) shows promise at least for relative dosimetry, as it is capable of high-resolution 3D dose mapping. Radiochromic film dosimetry is currently the best validated (Dempsey et al 2000) for both relative and absolute dose measurement of the emerging multidimensional detector systems.
Another emerging development is extension of Monte Carlo dose-computation methods from single-source dosimetry to treatment planning, i.e. calculation of patient-specific dose distributions based upon the actual locations of the implanted sources in the patient. In contrast to conventional single-source dose superposition calculations, Monte Carlo dose calculations can account for tissue-composition heterogeneities, applicator shielding and interseed attenuation. While occasional Monte Carlo studies have been published that address these issues , DeMarco et al 1999 , Markman et al 2001 , clinical use of Monte Carlo simulation has been limited by the long computing times required. Recently, accelerated Monte Carlo codes have been developed Williamson 2005, Hedtjarn et al 2002) , with single-processor running times as short as 2 min for clinically realistic implant geometries. For low-energy sources, a major problem is characterizing tissue heterogeneities, requires estimation of the photoelectric cross section as well as tissue density (Devic et al 2000) .
Conclusion
This highly selective review demonstrates that brachytherapy has been profoundly affected by mainstream advances in experimental, theoretical and computational physics as well as technological and clinical innovations specific to radiation therapy and medical physics. The broad areas of development include replacement of radium and radon sources with artificial radionuclides, the rise of quantitative dosimetry and treatment planning, and increased utilization of imaging in brachytherapy planning and delivery. Probably, the most influential of these developments was artificial radionuclides. Brachytherapy is essentially an invasive surgical procedure. The clinical need driving this development was not dose-delivery limitations: doses delivered by 1950s era brachytherapy procedures were often as high as or higher than those delivered today. Rather, the concerns were minimizing radiation exposure hazards (primarily to operator and staff), maximizing the flexibility of the implantation system and minimizing the required level of surgical skill, i.e., steepness and difficulty of the learning curve. The latter two issues impact the quality of implants (and hence local control) achievable and the accessibility of the technique to the population of eligible patients. Image guidance has been shown to significantly improve clinical outcomes, at least for prostate brachytherapy, compared to direct surgical exposure of the tumour. Another important achievement of the last 50 years is the remarkable evolution of brachytherapy dose computation from a semi-qualitative estimate of delivered dose based upon an idealized source arrangement to a physically realistic estimate with uncertainties of less than 5% for even the lowest energy photon-emitting sources. Progress in brachytherapy has resulted from an intersection of clinical need, technological capability and conceptual sophistication.
